Regeneron Pharmaceuticals, Inc.
Close on Nov 20, 2026Market cap $95.24BP/E 20.3Yield –
Regeneron Pharmaceuticals Direct Clinical R&D by Quarter
Direct Clinical R&D — EYLEA HD (aflibercept 8 mg) ($M) ($M)
Regeneron Pharmaceuticals Direct Clinical R&D: $16.5M in Q4 2025, down 26.0% from a year earlier.
Where the Q4 2025 figure comes from
Calculated from reported figures: Q4 = full year (10-K) − nine months (10-Q)
Source: Form 10-K (regn-20251231.htm; 0000872589-25-000028|regn-20250930.htm, filed 2026-02-04) ↗
Reported in Form 10-Q / 10-K MD&A — Research and Development Expenses by Clinical Program.
quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Cite this data
StockData. (2026). Regeneron Pharmaceuticals Direct Clinical R&D ($M), quarterly Q1 2022–Q4 2025 [Data set]. Compiled from Regeneron Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/regn/kpis/rd-prog-eylea-hd
See every metric in the Regeneron Pharmaceuticals KPI table. Data updated Nov 4, 2026.
See a number that looks wrong?